Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors

Transplant Proc. 1999 Feb-Mar;31(1-2):1210-3. doi: 10.1016/s0041-1345(98)02094-6.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Basiliximab
  • Cadaver
  • Cyclosporine / therapeutic use
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Graft Rejection / prevention & control*
  • Graft Survival
  • Histocompatibility Testing
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / mortality
  • Kidney Transplantation / physiology
  • Living Donors
  • Male
  • Middle Aged
  • Recombinant Fusion Proteins*
  • Retrospective Studies
  • Survival Analysis
  • Tissue Donors
  • United States

Substances

  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Cyclosporine
  • Basiliximab